Nicum, Shibani http://orcid.org/0000-0003-1125-405X
McGregor, Naomi
Austin, Rachel
Collins, Linda
Dutton, Susan
McNeish, Iain http://orcid.org/0000-0002-9387-7586
Glasspool, Rosalind http://orcid.org/0000-0002-5000-1680
Hall, Marcia http://orcid.org/0000-0003-0039-5041
Roux, Rene
Michael, Agnieszka http://orcid.org/0000-0002-7262-6227
Clamp, Andrew
Jayson, Gordon
Kristeleit, Rebecca http://orcid.org/0000-0003-3825-1326
Banerjee, Susana http://orcid.org/0000-0002-8840-7934
Mansouri, Anita
Funding for this research was provided by:
AstraZeneca (ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414, ESR-14-10414)
Article History
Received: 31 March 2023
Revised: 1 November 2023
Accepted: 21 December 2023
First Online: 20 January 2024
Competing interests
: Competing interests for each author have been declared.
: All patients provided written informed consent and agreed to collection of archival tissue and research bloods being taken. The trial was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) and London Chelsea Research Ethics Committee in 2017 (16/LO/2150) and has been conducted as part of the portfolio of trials in the registered UKCRC Oxford Clinical Trials Research Unit (OCTRU) at the University of Oxford. It followed their Standard Operating Procedures ensuring compliance with the principles of Good Clinical Practice and the Declaration of Helsinki and any applicable regulatory requirements.
: All data have been anonymised, and the manuscript does not contain any individually identifiable data.